Clinical research in the healthy aging area is of interest because consumers are increasingly demanding products that are both safe and credible. Rigorous science helps brands innovate responsibly, ensuring safety and efficacy, which ultimately strengthens brand reputation and loyalty.

Two key areas of interest for Aker BioMarine (Norway) are brain and muscle health.

“We are committed to advancing science-driven nutrition and exploring brain health through our innovative LPC ingredient, Lysoveta, as neurological disease continues to rise globally,” said Lisa Miller, global communications director at Aker BioMarine Human Ingredients.

With conditions now affecting around 40 percent of the world’s population and dementia expected to exceed 150 million cases by 2050, Aker BioMarine joined the Innovation Center for Neuroresilience (ICoN), led by the University of Bergen, to support prevention-focused research into neurodegenerative diseases, such as Parkinson’s and dementia.

“Through this collaboration, we contribute expertise in bioactive marine ingredients and translational research, aligned with ICoN’s emphasis on early detection, neuroprotection, and long-term prevention,” Miller said. “Central to this work is Lysoveta, a unique dietary ingredient that enhances delivery of LPC-bound DHA and EPA to the brain via the MfsD2a transporter, enabling these omega-3s to cross the blood–brain barrier efficiently. Beyond transport, LPC supports brain cell membranes, neuron communication, myelination, cellular repair, and key signaling pathways involved in inflammation, neuroprotection, and regeneration.”

In addition to brain health, Aker BioMarine worked with the University of Glasgow’s School of Medicine, Dentistry and Nursing to investigate whether long-chain omega-3 polyunsaturated fatty acids in krill oil help preserve muscle tissue during caloric restriction.

In a randomized, placebo-controlled trial, 52 adults aged 25-65 with above average BMIs (body mass indices) received either 4 g of Superba Boost krill oil or 4 g of vegetable oil daily, both before and during an alternate-day fasting diet.

Among the 41 participants who completed the trial, several tests were conducted after the weight-loss period including assessing handgrip strength, chair-rising ability, body composition and fatty acid composition.

The key findings included:

• Participants taking krill oil lost less muscle mass than those in the placebo group

• Loss of handgrip strength was lower in the krill oil group

• Chair-rise times were shorter for those taking krill oil

• Systolic blood pressure reduction was greater in the krill oil group

• Levels of EPA, DHA and omega-3 index were higher among those taking krill oil.

“These results suggest that krill oil supplementation may help preserve muscle mass and strength while supporting cardiovascular health during weight loss, highlighting the importance of advancing science and embracing exploration in developing GLP-1 companion solutions, which can lead to innovative approaches that enhance efficacy, safety, and personalized care,” Miller said.

For more information, visit www.akerbiomarine.com.

Feature